Study #2022-0650
A Phase 1, safety lead-in and randomized, open-label, Perioperative Study of Vorasidenib in combination with Pembrolizumab in subjects with recurrent or progressive IDH-1 mutant Astrocytomas
MD Anderson Study Status
Enrolling
Treatment Agent
Vorasidenib, Pembrolizumab
Description
Vorasidenib in combination with pembrolizumab in participants with recurrent or progressive isocitrate dehydrogenase-1 (IDH-1) mutant Glioma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Astrocytoma, Oligodendroglioma
Study phase:
Phase I
Physician name:
Vinaykumar Puduvalli
Department:
Neuro-Oncology
For general questions about clinical trials:
1-855-404-4637
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.